In contrast to endometrial serous carcinomas, where TP53 mutation is the early founder mutation and therefore present in any subclone, there are some endometrioid carcinomas with a mutator phenotype (either POLE ultramutated or mismatch repair deficient hypermutated) that can acquire a TP53 mutation later in the course. Here, TP53 is linked to endometrioid adenocarcinoma.